Please Wait.....
Report
Ophthalmic Topical Therapeutics Market Forecast till 2030
Market Report I 2023-11-15 I 148 Pages I Market Research Future
Ophthalmic Topical Therapeutics Market Forecast till 2030
Market Overview
The Ophthalmic Topical Therapeutics is estimated to register a significant CAGR of 7.25% during the forecast period (2023 - 2030).
This market is being driven by a few elements, remembering an ascent for geriatric populace and expanding pervasiveness of ophthalmic problems.
There is a rising commonness of ophthalmic problems like refractive blunders, dry eye, glaucoma, eye sensitivities, and age-related macular degeneration internationally which is driving the market development. As per the WHO in October 2021, somewhere around 2.2 billion individuals universally experience the ill effects of vision weakness. The main sources of vision hindrance are refractive blunders and waterfall, the two of which have topical ophthalmic restorative items accessible on the lookout. Essentially, glaucoma is a main source of irreversible visual impairment universally. As indicated by Public Glaucoma Exploration, north of 3 million Americans have glaucoma. As per the WHO in 2021, over 7.7 million individuals experience the ill effects of glaucoma worldwide. The most widely recognized treatment for glaucoma is remedy eye drops like beta-blockers, prostaglandins, Rho-kinase inhibitors, and others that can hold glaucoma back from deteriorating.
Market Segmentation
The Market fragments of Ophthalmic Topical Therapeutics, based on type, incorporates fake tears, against sensitivity, anti-toxin drops, mitigating, antiglaucoma, and others. The Market division, in view of disease type, incorporates dry eye, eye sensitivity, glaucoma, eye disease, retinal issues, uveitis, and others. In view of dose form, the worldwide ophthalmic topical therapeutics industry is divided into eye drops, gels, salves, and others.
The Market division of Ophthalmic Topical Therapeutics, in view of distribution channel, incorporates clinic drug stores, pharmacies, online drug stores, and others.
Regional Insights
The North America ophthalmic topical therapeutics market represented the biggest piece of the pie in 2022. Key variables credited to its rising commonness of eye sickness, rising geriatric populace, and the presence of an enormous number of market players in the district. Moreover, the rising commonness of ophthalmic illnesses is driving the market interest for ophthalmic topical therapeutics in North America. Factors like an expansion in the geriatric populace, progressions in innovative work in optometry, and the expansion in the utilization of ophthalmic medications in emergency clinic drug stores are supposed to expand the interest for ophthalmic topical therapeutics in the US.
Europe ophthalmic topical therapeutics market represented the second-biggest piece of the pie because of expanding geriatric populace in the created nations, globalization of medical services, and rising weight of diabetes and other comorbidities.
The Asia-Pacific ophthalmic topical therapeutics market is supposed to be the quickest developing from 2023 to 2030 because of the rising expanding weight of ophthalmic problems and rising buyer mindfulness, and the developing reception of cutting-edge innovations. Organizations are going into key drives to create and popularize new treatment choices for patients.
Major Players
Key Companies in the market of ophthalmic topical therapeutics includes Santen pharmaceutical co., Ltd. (Japan), Sun Pharmaceutical Industries Ltd (India), Novartis AG (Switzerland), AbbVie (US), Bausch & Lomb Incorporated (US), Amneal Pharmaceuticals., LLC (US), Teva Pharmaceutical Industries Ltd. (Israel), Alcon (Switzerland), Akorn Operating Company LLC (US), and Viatris Inc. (US).
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
1.1 OVERVIEW
2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE
2.5 ASSUMPTIONS & LIMITATIONS
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 SECONDARY RESEARCH
3.3 PRIMARY RESEARCH
3.4 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
3.6.1 BOTTOM-UP APPROACH
3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION
4 MARKET DYNAMICS
4.1 OVERVIEW
4.2 DRIVERS
4.2.1 RISE IN GERIATRIC POPULATION
4.2.2 INCREASING PREVALENCE OF OPHTHALMIC DISORDERS
4.3 RESTRAINTS
4.3.1 LACK OF AWARENESS REGARDING EYE DISORDERS
4.4 OPPORTUNITIES
4.4.1 GROWING NUMBER OF TOPICAL DRUGS IN THE PIPELINE
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS
5.1.1 R&D
5.1.2 MANUFACTURING
5.1.3 DISTRIBUTION & SALES
5.1.4 POST-SALES MONITORING
5.2 PORTER'S FIVE FORCES MODEL
5.2.1 THREAT OF NEW ENTRANTS
5.2.2 BARGAINING POWER OF SUPPLIERS
5.2.3 THREAT OF SUBSTITUTES
5.2.4 BARGAINING POWER OF BUYERS
5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19 ON THE OPHTHALMIC TOPICAL THERAPEUTICS MARKET
5.3.1 IMPACT ON SUPPLY CHAIN
5.3.2 IMPACT ON PRODUCTTION
5.3.3 IMPACT ON MARKET PLAYERS
6 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY PRODUCT TYPE
6.1 OVERVIEW
6.2 ARTIFICIAL TEARS
6.3 ANTI-ALLERGY
6.4 ANTIBIOTIC DROPS
6.5 ANTI-INFLAMMATORY
6.6 ANTIGLAUCOMA
6.7 OTHERS
7 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE
7.1 OVERVIEW
7.2 DRY EYE
7.3 EYE ALLERGY
7.4 GLAUCOMA
7.5 EYE INFECTION
7.6 RETINAL DISORDERS
7.7 UVEITIS
7.8 OTHERS
8 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM
8.1 OVERVIEW
8.2 EYE DROPS
8.3 GELS
8.4 OINTMENTS
8.5 OTHERS
9 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL
9.1 OVERVIEW
9.2 HOSPITAL PHARMACIES
9.3 DRUG STORES
9.4 ONLINE PHARMACIES
9.5 OTHERS
10 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY REGION
10.1 OVERVIEW
10.2 NORTH AMERICA
10.2.1 US
10.2.2 CANADA
10.3 EUROPE
10.3.1 GERMANY
10.3.2 UK
10.3.3 FRANCE
10.3.4 ITALY
10.3.5 SPAIN
10.3.6 REST OF EUROPE
10.4 ASIA-PACIFIC
10.4.1 JAPAN
10.4.2 CHINA
10.4.3 INDIA
10.4.4 AUSTRALIA
10.4.5 SOUTH KOREA
10.4.6 REST OF ASIA-PACIFIC
10.5 REST OF THE WORLD
10.5.1 MIDDLE EAST
10.5.2 AFRICA
10.5.3 LATIN AMERICA
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 COMPETITIVE BENCHMARKING
11.3 MAJOR GROWTH STRATEGY IN GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET
11.4 THE LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET
11.5 KEY DEVELOPMENT ANALYSIS
11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
11.6.1 PRODUCT APPROVALS AND PRODUCT LAUNCHES/PIPELINE DRUGS
11.6.2 PARTNERSHIP/COLLABORATION
11.6.3 BUSINESS EXPANSIONS/AGREEMENTS
11.6.4 MERGERS & ACQUISITIONS
11.7 MAJOR PLAYERS SALES ANALYSIS
11.7.1 SALES & OPERATING INCOME
11.8 MAJOR PLAYERS R&D ANALYSIS
12 COMPANY PROFILES
12.1 SANTEN PHARMACEUTICAL CO., LTD.
12.1.1 COMPANY OVERVIEW
12.1.2 FINANCIAL OVERVIEW
12.1.3 PRODUCTS/SERVICES OFFERED
12.1.4 KEY DEVELOPMENTS
12.1.5 KEY STRATEGIES
12.2 SUN PHARMACEUTICAL INDUSTRIES LTD
12.2.1 COMPANY OVERVIEW
12.2.2 FINANCIAL OVERVIEW
12.2.3 PRODUCTS/SERVICES OFFERED
12.2.4 KEY DEVELOPMENTS
12.2.5 KEY STRATEGIES
12.3 NOVARTIS AG
12.3.1 COMPANY OVERVIEWS
12.3.2 FINANCIAL OVERVIEW
12.3.3 PRODUCTS/SERVICES OFFERED
12.3.4 KEY DEVELOPMENTS
12.3.5 SWOT ANALYSIS
12.3.6 KEY STRATEGIES
12.4 ABBVIE INC.
12.4.1 COMPANY OVERVIEW
12.4.2 FINANCIAL OVERVIEW
12.4.3 PRODUCTS OFFERED
12.4.4 KEY DEVELOPMENTS
12.4.5 SWOT ANALYSIS
12.4.6 KEY STRATEGIES
12.5 BAUSCH & LOMB INCORPORATED
12.5.1 COMPANY OVERVIEW
12.5.2 FINANCIAL OVERVIEW
12.5.3 PRODUCTS OFFERED
12.5.4 KEY DEVELOPMENTS
12.5.5 SWOT ANALYSIS
12.5.6 KEY STRATEGIES
12.6 AMNEAL PHARMACEUTICALS LLC.
12.6.1 COMPANY OVERVIEW
12.6.2 FINANCIAL OVERVIEW
12.6.3 PRODUCTS/SERVICES OFFERED
12.6.4 KEY DEVELOPMENTS
12.6.5 KEY STRATEGIES
12.7 TEVA PHARMACEUTICAL INDUSTRIES LTD.
12.7.1 COMPANY OVERVIEW
12.7.2 FINANCIAL ANALYSIS
12.7.3 PRODUCTS/SERVICES/SOLUTIONS OFFERED
12.7.4 KEY DEVELOPMENTS
12.7.5 SWOT ANALYSIS
12.7.6 KEY STRATEGIES
12.8 ALCON
12.8.1 COMPANY OVERVIEW
12.8.2 FINANCIAL OVERVIEW
12.8.3 PRODUCTS/SERVICES/SOLUTIONS 0FFERED
12.8.4 KEY DEVELOPMENTS
12.8.5 SWOT ANALYSIS
12.8.6 KEY STRATEGIES
12.9 AKORN OPERATING COMPANY LLC
12.9.1 COMPANY OVERVIEW
12.9.2 FINANCIAL OVERVIEW
12.9.3 PRODUCTS/SERVICES/SOLUTIONS OFFERED
12.9.4 KEY DEVELOPMENTS
12.9.5 KEY STRATEGIES
12.10 VIATRIS INC.
12.10.1 COMPANY OVERVIEW
12.10.2 FINANCIAL OVERVIEW
12.10.3 PRODUCTS/SERVICES OFFERED
12.10.4 KEY DEVELOPMENTS
12.10.5 KEY STRATEGIES
13 APPENDIX
13.1 REFERENCES
13.2 RELATED REPORTS
LIST OF TABLES
TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS
TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
TABLE 3 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019-2030 (USD BILLION)
TABLE 4 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR ARTIFICIAL TEARS, BY REGION, 2019-2030 (USD BILLION)
TABLE 5 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR ANTI-ALLERGY, BY REGION, 2019-2030 (USD BILLION)
TABLE 6 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR ANTIBIOTIC DROPS, BY REGION, 2019-2030 (USD BILLION)
TABLE 7 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR ANTI-INFLAMMATORY, BY REGION, 2019-2030 (USD BILLION)
TABLE 8 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR ANTIGLAUCOMA, BY REGION, 2019-2030 (USD BILLION)
TABLE 9 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR OTHERS, BY REGION, 2019-2030 (USD BILLION)
TABLE 10 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE, 2019-2030 (USD BILLION)
TABLE 11 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR DRY EYE, BY REGION, 2019-2030 (USD BILLION)
TABLE 12 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR EYE ALLERGY, BY REGION, 2019-2030 (USD BILLION)
TABLE 13 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR GLAUCOMA, BY REGION, 2019-2030 (USD BILLION)
TABLE 14 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR EYE INFECTION, BY REGION, 2019-2030 (USD BILLION)
TABLE 15 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR RETINAL DISORDERS, BY REGION, 2019-2030 (USD BILLION)
TABLE 16 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR UVEITIS, BY REGION, 2019-2030 (USD BILLION)
TABLE 17 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR OTHERS, BY REGION, 2019-2030 (USD BILLION)
TABLE 18 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM, 2019-2030 (USD BILLION)
TABLE 19 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR EYE DROPS, BY REGION, 2019-2030 (USD BILLION)
TABLE 20 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR GELS, BY REGION, 2019-2030 (USD BILLION)
TABLE 21 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR OINTMENTS, BY REGION, 22019-2030 (USD BILLION)
TABLE 22 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR OTHERS, BY REGION, 2019-2030 (USD BILLION)
TABLE 23 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2030 (USD BILLION)
TABLE 24 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR HOSPITAL PHARMACIES, BY REGION, 2019-2030 (USD BILLION)
TABLE 25 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR DRUG STORES, BY REGION, 2019-2030 (USD BILLION)
TABLE 26 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR ONLINE PHARMACIES, BY REGION, 2019-2030 (USD BILLION)
TABLE 27 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR OTHERS, BY REGION, 2019-2030 (USD BILLION)
TABLE 28 GLOBAL: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY REGION, 2019-2030 (USD BILLION)
TABLE 29 NORTH AMERICA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY COUNTRY, 2019-2030 (USD BILLION)
TABLE 30 NORTH AMERICA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019-2030 (USD BILLION)
TABLE 31 NORTH AMERICA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE, 2019-2030 (USD BILLION)
TABLE 32 NORTH AMERICA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM, 2019-2030 (USD BILLION)
TABLE 33 NORTH AMERICA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2030 (USD BILLION)
TABLE 34 US: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019-2030 (USD BILLION)
TABLE 35 US: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE, 2019-2030 (USD BILLION)
TABLE 36 US: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM, 2019-2030 (USD BILLION)
TABLE 37 US: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2030 (USD BILLION)
TABLE 38 CANADA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019-2030 (USD BILLION)
TABLE 39 CANADA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE, 2019-2030 (USD BILLION)
TABLE 40 CANADA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM, 2019-2030 (USD BILLION)
TABLE 41 CANADA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2030 (USD BILLION)
TABLE 42 EUROPE: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY COUNTRY, 2019-2030 (USD BILLION)
TABLE 43 EUROPE: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019-2030 (USD BILLION)
TABLE 44 EUROPE: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE, 2019-2030 (USD BILLION)
TABLE 45 EUROPE: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM, 2019-2030 (USD BILLION)
TABLE 46 EUROPE: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2030 (USD BILLION)
TABLE 47 GERMANY: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019-2030 (USD BILLION)
TABLE 48 GERMANY: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE, 2019-2030 (USD BILLION)
TABLE 49 GERMANY: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM, 2019-2030 (USD BILLION)
TABLE 50 GERMANY: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2030 (USD BILLION)
TABLE 51 UK: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019-2030 (USD BILLION)
TABLE 52 UK: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE, 2019-2030 (USD BILLION)
TABLE 53 UK: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM, 2019-2030 (USD BILLION)
TABLE 54 UK: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2030 (USD BILLION)
TABLE 55 FRANCE: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019-2030 (USD BILLION)
TABLE 56 FRANCE: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE, 2019-2030 (USD BILLION)
TABLE 57 FRANCE: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM, 2019-2030 (USD BILLION)
TABLE 58 FRANCE: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2030 (USD BILLION)
TABLE 59 ITALY: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019-2030 (USD BILLION)
TABLE 60 ITALY: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE, 2019-2030 (USD BILLION)
TABLE 61 ITALY: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM, 2019-2030 (USD BILLION)
TABLE 62 ITALY: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2030 (USD BILLION)
TABLE 63 SPAIN: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019-2030 (USD BILLION)
TABLE 64 SPAIN: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE, 2019-2030 (USD BILLION)
TABLE 65 SPAIN: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM, 2019-2030 (USD BILLION)
TABLE 66 SPAIN: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2030 (USD BILLION)
TABLE 67 REST OF EUROPE: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019-2030 (USD BILLION)
TABLE 68 REST OF EUROPE: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE, 2019-2030 (USD BILLION)
TABLE 69 REST OF EUROPE: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM, 2019-2030 (USD BILLION)
TABLE 70 REST OF EUROPE: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2030 (USD BILLION)
TABLE 71 ASIA-PACIFIC: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY COUNTRY, 2019-2030 (USD BILLION)
TABLE 72 ASIA-PACIFIC: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019-2030 (USD BILLION)
TABLE 73 ASIA-PACIFIC: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE, 2019-2030 (USD BILLION)
TABLE 74 ASIA-PACIFIC: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM, 2019-2030 (USD BILLION)
TABLE 75 ASIA-PACIFIC: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2030 (USD BILLION)
TABLE 76 JAPAN: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DEVICE TYPE, 2019-2030(USD BILLION)
TABLE 77 JAPAN: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE, 2019-2030(USD BILLION)
TABLE 78 JAPAN: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM, 2019-2030(USD BILLION)
TABLE 79 JAPAN: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2030 (USD BILLION)
TABLE 80 CHINA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DEVICE TYPE, 2019-2030(USD BILLION)
TABLE 81 CHINA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE, 2019-2030(USD BILLION)
TABLE 82 CHINA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM, 2019-2030(USD BILLION)
TABLE 83 CHINA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2030 (USD BILLION)
TABLE 84 INDIA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DEVICE TYPE, 2019-2030(USD BILLION)
TABLE 85 INDIA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE, 2019-2030(USD BILLION)
TABLE 86 INDIA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM, 2019-2030(USD BILLION)
TABLE 87 INDIA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2030 (USD BILLION)
TABLE 88 AUSTRALIA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DEVICE TYPE, 2019-2030(USD BILLION)
TABLE 89 AUSTRALIA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE, 2019-2030 (USD BILLION)
TABLE 90 AUSTRALIA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM, 2019-2030(USD BILLION)
TABLE 91 AUSTRALIA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2030(USD BILLION)
TABLE 92 SOUTH KOREA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DEVICE TYPE, 2019-2030 (USD BILLION)
TABLE 93 SOUTH KOREA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE, 2019-2030 (USD BILLION)
TABLE 94 SOUTH KOREA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM, 2019-2030 (USD BILLION)
TABLE 95 SOUTH KOREA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2030(USD BILLION)
TABLE 96 REST OF ASIA-PACIFIC: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DEVICE TYPE, 2019-2030(USD BILLION)
TABLE 97 REST OF ASIA-PACIFIC: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE, 2019-2030(USD BILLION)
TABLE 98 REST OF ASIA-PACIFIC: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM, 2019-2030(USD BILLION)
TABLE 99 REST OF ASIA-PACIFIC: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2030(USD BILLION)
TABLE 100 REST OF THE WORLD: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY COUNTRY 2019-2030(USD BILLION)
TABLE 101 REST OF THE WORLD: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY PRODUCT TYPE 2019-2030(USD BILLION)
TABLE 102 REST OF THE WORLD: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE 2019-2030(USD BILLION)
TABLE 103 REST OF THE WORLD: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM 2019-2030(USD BILLION)
TABLE 104 REST OF THE WORLD: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL 2019-2030(USD BILLION)
TABLE 105 MIDDLE EAST: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY PRODUCT TYPE 2019-2030 (USD BILLION)
TABLE 106 MIDDLE EAST: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE 2019-2030 (USD BILLION)
TABLE 107 MIDDLE EAST: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM 2019-2030(USD BILLION)
TABLE 108 MIDDLE EAST: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL 2019-2030(USD BILLION)
TABLE 109 AFRICA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY PRODUCT TYPE 2019-2030 (USD BILLION)
TABLE 110 AFRICA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE 2019-2030(USD BILLION)
TABLE 111 AFRICA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM 2019-2030(USD BILLION)
TABLE 112 AFRICA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL 2019-2030 (USD BILLION)
TABLE 113 LATIN AMERICA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY PRODUCT TYPE 2019-2030 (USD BILLION)
TABLE 114 LATIN AMERICA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE 2019-2030 (USD BILLION)
TABLE 115 LATIN AMERICA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM 2019-2030 (USD BILLION)
TABLE 116 LATIN AMERICA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL 2019-2030(USD BILLION)
TABLE 117 MAJOR MANUFACTURERS IN GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET
TABLE 118 MOST ACTIVE PLAYER IN GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET
TABLE 119 PRODUCT APPROVALS AND PRODUCT LAUNCHES/PIPELINE DRUGS
TABLE 120 PARTNERSHIP/COLLABORATION
TABLE 121 BUSINESS EXPANSIONS/ AGREEMENTS
TABLE 122 MERGERS & ACQUISITIONS
TABLE 123 SANTEN PHARMACEUTICAL CO., LTD.: PRODUCTS OFFERED
TABLE 124 SANTEN PHARMACEUTICAL CO., LTD.: KEY DEVELOPMENTS
TABLE 125 SUN PHARMACEUTICAL INDUSTRIES LTD: PRODUCTS OFFERED
TABLE 126 GENENTECH, INC.: KEY DEVELOPMENTS
TABLE 127 NOVARTIS AG: PRODUCTS OFFERED
TABLE 128 NOVARTIS AG.: KEY DEVELOPMENTS
TABLE 129 ABBVIE INC.: PRODUCTS OFFERED
TABLE 130 ABBVIE INC.: KEY DEVELOPMENTS
TABLE 131 BAUSCH & LOMB INCORPORATED: PRODUCTS OFFERED
TABLE 132 BAUSCH & LOMB INCORPORATED: KEY DEVELOPMENTS
TABLE 133 AMNEAL PHARMACEUTICALS LLC.: PRODUCTS OFFERED
TABLE 134 AMNEAL PHARMACEUTICALS., LLC.: KEY DEVELOPMENTS
TABLE 135 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 136 TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY DEVELOPMENTS
TABLE 137 ALCON: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 138 ALCON: KEY DEVELOPMENTS
TABLE 139 AKORN OPERATING COMPANY LLC: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 140 VIATRIS INC.: PRODUCTS/SERVICES OFFERED
TABLE 141 VIATRIS INC.: KEY DEVELOPMENTS
LIST OF FIGURES
FIGURE 1 MARKET SYNOPSIS
FIGURE 2 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET
FIGURE 3 BOTTOM-UP AND TOP-DOWN APPROACHES
FIGURE 4 MARKET DYNAMICS: OPHTHALMIC TOPICAL THERAPEUTICS MARKET
FIGURE 5 DRIVERS: IMPACT ANALYSIS
FIGURE 6 RESTRAINT: IMPACT ANALYSIS
FIGURE 7 VALUE CHAIN ANALYSIS: GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET
FIGURE 8 PORTER'S FIVE FORCES ANALYSIS: GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET
FIGURE 9 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2022 & 2030 (USD BILLION)
FIGURE 10 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET SHARE (%), BY PRODUCT TYPE, 2022
FIGURE 11 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE, 2022 & 2030 (USD BILLION)
FIGURE 12 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET SHARE (%), BY DISEASE TYPE, 2022
FIGURE 13 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM, 2022 & 2030 (USD BILLION)
FIGURE 14 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET SHARE (%), BY DOSAGE FORM, 2022
FIGURE 15 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022 & 2030 (USD BILLION)
FIGURE 16 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET SHARE (%), BY DISTRIBUTION CHANNEL, 2021
FIGURE 17 GLOBAL: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY REGION 2022 & 2030 (USD BILLION)
FIGURE 18 GLOBAL: OPHTHALMIC TOPICAL THERAPEUTICS MARKET SHARE (%), BY REGION 2022
FIGURE 19 NORTH AMERICA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET SHARE (%), BY COUNTRY, 2022
FIGURE 20 EUROPE: OPHTHALMIC TOPICAL THERAPEUTICS MARKET SHARE (%), BY COUNTRY, 2022
FIGURE 21 ASIA-PACIFIC: OPHTHALMIC TOPICAL THERAPEUTICS MARKET SHARE (%), BY COUNTRY, 2022
FIGURE 22 REST OF THE WORLD: OPHTHALMIC TOPICAL THERAPEUTICS MARKET SHARE (%), BY COUNTRY, 2022
FIGURE 23 BENCHMARKING OF MAJOR COMPETITORS
FIGURE 24 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET
FIGURE 25 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET: COMPETITIVE LANDSCAPE
FIGURE 26 MAJOR PLAYERS SALES & OPERATING INCOME, 2022 (USD BILLION)
FIGURE 27 MAJOR PLAYERS R&D EXPENDITURE, 2022 (USD BILLION)
FIGURE 28 SANTEN PHARMACEUTICAL CO., LTD.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 29 SUN PHARMACEUTICAL INDUSTRIES LTD: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 30 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 31 NOVARTIS AG.: SWOT ANALYSIS
FIGURE 32 ABBVIE INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 33 ABBVIE INC.: SWOT ANALYSIS
FIGURE 34 BAUSCH & LOMB INCORPORATED: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 35 BAUSCH & LOMB INCORPORATED: SWOT ANALYSIS
FIGURE 36 AMNEAL PHARMACEUTICALS LLC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 37 TEVA PHARMACEUTICAL INDUSTRIES LTD.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 38 TEVA PHARMACEUTICAL INDUSTRIES LTD.: SWOT ANALYSIS
FIGURE 39 ALCON: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 40 ALCON: SWOT ANALYSIS
FIGURE 41 VIATRIS INC.: FINANCIAL OVERVIEW SNAPSHOT
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security